|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-4-7
|
|
pubmed:abstractText |
Gemcitabine- and 5-fluorouracil (5-FU)- based chemotherapy is a commonly used adjuvant or palliative treatment for patients with pancreatic cancer. However, a standard chemotherapy regimen has yet to be developed for patients refractory to gemcitabine and 5-FU treatment. We attempted to evaluate the efficacy and safety of a combination of irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU- refractory pancreatic cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1573-0646
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
343-9
|
|
pubmed:meshHeading |
pubmed-meshheading:19444385-Adenocarcinoma,
pubmed-meshheading:19444385-Aged,
pubmed-meshheading:19444385-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19444385-Camptothecin,
pubmed-meshheading:19444385-Deoxycytidine,
pubmed-meshheading:19444385-Disease-Free Survival,
pubmed-meshheading:19444385-Dose-Response Relationship, Drug,
pubmed-meshheading:19444385-Drug Resistance, Neoplasm,
pubmed-meshheading:19444385-Female,
pubmed-meshheading:19444385-Fluorouracil,
pubmed-meshheading:19444385-Humans,
pubmed-meshheading:19444385-Male,
pubmed-meshheading:19444385-Middle Aged,
pubmed-meshheading:19444385-Organoplatinum Compounds,
pubmed-meshheading:19444385-Pancreatic Neoplasms,
pubmed-meshheading:19444385-Pilot Projects,
pubmed-meshheading:19444385-Salvage Therapy,
pubmed-meshheading:19444385-Survival Analysis
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
|
|
pubmed:affiliation |
Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
